Slide 1: Teleflex Incorporated Company Overview
TELEFLEX INCORPORATED Company Overview Exhibit 99.1
Slide 2: Forward-Looking Statements
2 This presentation and our discussion contain forward-looking information and statements including, but not limited to, longer-term growth and profitability objectives over the next 5 years, including, achievement of constant currency revenue growth of greater-than 5%, gross margins of approximatel
Slide 3: Agenda
3 Agenda Company Overview Strategic Objectives Financial Review Question and Answer Summary
Slide 4: Company Overview
4 COMPANY OVERVIEW
Slide 5: Our Mission
5 Our Mission Enhance patient outcomes by providing products that help clinicians improve clinical results and reduce procedural costs Act as a partner and a trusted resource for our customers
Slide 6: Our Company
Our Company 6 CVC PICC Arterial Lines Dialysis Catheter Positioning Ultrasound Intra Aortic Balloon Pumps IAB Catheters Vascular Access Urology Surgical Cardiac Care OEM Foley Catheters Urinary Collection Devices Intermittent Catheters Hydrophilic Catheters Ligation Closure Devices Chest Drainage Ge
Slide 7: Our Markets
Our Markets 2011 Revenue: $1.529 Billion Hospitals / Healthcare Providers Medical Device Manufacturers Home Health 0.81 0.11 0.08 U.S. EMEA Asia / Latin America / Canada 0.52 0.36 0.12 United States Europe, Middle East, Africa Asia, Latin America, Canada Hospitals and Healthcare Providers Medical De
Slide 8: Significant Market Opportunities
Significant Market Opportunities Surgical Respiratory Anesthesia Vascular Access Urology Cardiac 0.35 0.18 0.17 0.15 0.12 0.03 Medical Device Market Size Sales = $10.3 billion 1 Market Drivers Global demographics Aging population Rising standard of living in emerging markets Increasing demand for me
Slide 9: Strategic Objectives
9 STRATEGIC OBJECTIVES
Slide 10: Longer-term Growth and Profitability Objectives
10 Constant currency revenue growth of > 5% Gross margins of approximately 55% Research and development expense of approximately 5% Return on equity of approximately 15% Operating margins of approximately 25% Longer-term Growth and Profitability Objectives
Slide 11: Capital Allocation Strategy
11 Strategic and technology acquisitions Internal investment in innovation and people Reduction of outstanding debt Return of capital to shareholders via dividends Capital Allocation Strategy
Slide 12: 2011 - 2012 New Product & Line Extensions
12 2011 - 2012 New Product & Line Extensions 2011 7 Vascular 6 Anesthesia/Respiratory 3 Surgical 3 Urology 3 Specialty 14 Vascular 16 Anesthesia/Respiratory 6 Surgical 3 Specialty 2012 1 Cardiac
Slide 13: Financial Review
13 FINANCIAL REVIEW
Slide 14: Full year 2011 year-over-year review
14 Full year 2011 year-over-year review 1 % change over full year 2010 results.
Slide 15: Summary
15 SUMMARY
Slide 16: TFX - Positioned for Value Creation
Transformation to pure-play global med-tech company complete Focus on products that enable providers to improve outcomes and enhance safety Acceleration of R&D and Sales and Marketing investments Technology driven Pipeline development Product-line extensions Leverage Global brands Licensing / Partne
Slide 17: Question & Answer
17 QUESTION & ANSWER
Slide 18: Thank you for your attention
Thank you for your attent Teleflex:
Slide 19: Appendix
19 APPENDIX
Slide 20: Reconciliation of Constant Currency Revenue Growth
20 Reconciliation of Constant Currency Revenue Growth
Slide 21: Reconciliation of Gross Profit
21 Reconciliation of Gross Profit
Slide 22: Reconciliation of Operating Profit
22 Reconciliation of Operating Profit
Slide 23: Full Year EPS Reconciliation from Continuing Operations
23 Full Year EPS Reconciliation from Continuing Operations In 2011, losses and other charges include approximately $9.8 million, net of tax, or $0.24 per share, related to the loss on extinguishment of debt; approximately $3.5 million, net of tax, or $0.09 per share, in charges related to severance